# Italia Bongarzone

List of Publications by Year
in descending order



| | | | |
|---|---|---|---|
| 85 papers | 4,979 citations | 101543 36 h-index | 88630 70 g-index |
| 88 all docs | 88 docs citations | 88 times ranked | 5614 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell, 1990, 60, 557-563. | 28.9 | 905 |
| 2 | Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features. American Journal of Pathology, 1999, 155, 1967-1976. | 3.8 | 364 |
| 3 | Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.. Molecular and Cellular Biology, 1993, 13, 358-366. | 2.3 | 251 |
| 4 | Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene, 2004, 23, 7436-7440. | 5.9 | 239 |
| 5 | Loss of function effect of RET mutations causing Hirschsprung disease. Nature Genetics, 1995, 10, 35-40. | 21.4 | 225 |
| 6 | Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes and Cancer, 1996, 16, 1-14. | 2.8 | 152 |
| 7 | Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2006-2009. | 3.6 | 130 |
| 8 | Improved Clinical Outcome in Indolent B-Cell Lymphoma Patients Vaccinated with Autologous Tumor Cells Experiencing Immunogenic Death. Cancer Research, 2010, 70, 9062-9072. | 0.9 | 126 |
| 9 | Identification of Shc docking site on Ret tyrosine kinase. Oncogene, 1997, 14, 773-782. | 5.9 | 109 |
| 10 | Insular Carcinoma. American Journal of Surgical Pathology, 1997, 21, 1466-1473. | 3.7 | 109 |
| 11 | A Sequence Analysis of the Genomic Regions Involved in the Rearrangements between TPM3 and NTRK1 Genes Producing TRK Oncogenes in Papillary Thyroid Carcinomas. Genomics, 1995, 28, 15-24. | 2.9 | 101 |
| 12 | The ALCAM Shedding by the Metalloprotease ADAM17/TACE Is Involved in Motility of Ovarian Carcinoma Cells. Molecular Cancer Research, 2007, 5, 1246-1253. | 3.4 | 95 |
| 13 | Bioinformatics tools for secretome analysis. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2442-2453. | 2.3 | 93 |
| 14 | Identification of MET and SRC Activation in Melanoma Cell Lines Showing Primary Resistance to PLX4032. Neoplasia, 2011, 13, 1132-IN17. | 5.3 | 89 |
| 15 | Impact of biospecimens handling on biomarker research in breast cancer. BMC Cancer, 2009, 9, 409. | 2.6 | 81 |
| 16 | Chromosome I rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes and Cancer, 1997, 19, 112-123. | 2.8 | 78 |
| 17 | trk andret proto-oncogene expression in human neuroblastoma specimens: High frequency oftrk expression in non-advanced stages. International Journal of Cancer, 1993, 54, 540-545. | 5.1 | 77 |
| 18 | Human Glial Cell Line-derived Neurotrophic Factor Receptor Î±4 Is the Receptor for Persephin and Is Predominantly Expressed in Normal and Malignant Thyroid Medullary Cells. Journal of Biological Chemistry, 2001, 276, 9344-9351. | 3.4 | 77 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | RET Is Constitutively Activated by Novel Tandem Mutations that Alter the Active Site Resulting in Multiple Endocrine Neoplasia Type 2B. Cancer Research, 2006, 66, 10179-10187. | 0.9 | 73 |
| 20 | Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative. Journal of Proteome Research, 2017, 16, 4319-4329. | 3.7 | 66 |
| 21 | The two genes generatingRET/PTC3 are localized in chromosomal band 10q11.2. Genes Chromosomes and Cancer, 1994, 11, 51-57. | 2.8 | 65 |
| 22 | Regulation of Breast Cancer Response to Chemotherapy by Fibulin-1. Cancer Research, 2007, 67, 4271-4277. | 0.9 | 59 |
| 23 | Full activation of MEN2B mutant RET by an additional MEN2A mutation or by ligand GDNF stimulation. Oncogene, 1998, 16, 2295-2301. | 5.9 | 58 |
| 24 | Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. Journal of Endocrinological Investigation, 1995, 18, 130-133. | 3.3 | 57 |
| 25 | Internalization and recycling of ALCAM/CD166 detected by a fully human single-chain recombinant antibody. Journal of Cell Science, 2005, 118, 1515-1525. | 2.0 | 55 |
| 26 | Hepcidin and ferritin blood level as noninvasive tools for predicting breast cancer. Annals of Oncology, 2014, 25, 352-357. | 1.2 | 53 |
| 27 | Induction of RET Proto-Oncogene Expression in Neuroblastoma Cells Precedes Neuronal Differentiation and Is Not Mediated by Protein Synthesis. Experimental Cell Research, 1995, 217, 92-99. | 2.6 | 52 |
| 28 | Comparison of the Breakpoint Regions of ELE1 and RET Genes Involved in the Generation of RET/PTC3 Oncogene in Sporadic and in Radiation-Associated Papillary Thyroid Carcinomas. Genomics, 1997, 42, 252-259. | 2.9 | 50 |
| 29 | Secretome Compartment Is a Valuable Source of Biomarkers for Cancer-Relevant Pathways. Journal of Proteome Research, 2011, 10, 4196-4207. | 3.7 | 47 |
| 30 | Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosomes and Cancer, 1992, 5, 212-218. | 2.8 | 45 |
| 31 | MIF/CD74 axis is a target for novel therapies in colon carcinomatosis. Journal of Experimental and Clinical Cancer Research, 2017, 36, 16. | 8.6 | 43 |
| 32 | 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas. Cancer Immunology, Immunotherapy, 2005, 54, 1200-1213. | 4.2 | 39 |
| 33 | A t(2;3)(q12â€“13;p24â€“25) in follicular thyroid adenomas. Cancer Genetics and Cytogenetics, 1992, 64, 38-41. | 1.0 | 38 |
| 34 | PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting. Cancer Research, 2003, 63, 2234-43. | 0.9 | 38 |
| 35 | The RetC620R Mutation Affects Renal and Enteric Development in a Mouse Model of Hirschsprung's Disease. American Journal of Pathology, 2006, 168, 1262-1275. | 3.8 | 37 |
| 36 | Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. Oncogene, 1997, 14, 2609-2612. | 5.9 | 36 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Molecular predictors of response and outcome in ovarian cancer. Critical Reviews in Oncology/Hematology, 2006, 60, 19-37. | 4.4 | 36 |
| 38 | Dasatinib reduces FAK phosphorylation increasing the effects of RPI-1 inhibition in a RET/PTC1-expressing cell line. Molecular Cancer, 2010, 9, 278. | 19.2 | 36 |
| 39 | Tyrosines outside the Kinase Core and Dimerization Are Required for the Mitogenic Activity of RET/ptc2. Journal of Biological Chemistry, 1995, 270, 24642-24645. | 3.4 | 35 |
| 40 | Molecular characterization of LASP-1 expression reveals vimentin as its new partner in human hepatocellular carcinoma cells. International Journal of Oncology, 2015, 46, 1901-1912. | 3.3 | 31 |
| 41 | Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. Blood, 2011, 118, 4421-4430. | 1.4 | 30 |
| 42 | The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein. Oncogene, 1999, 18, 4833-4838. | 5.9 | 28 |
| 43 | Is Wilms Tumor a Candidate Neoplasia for Treatment with WNT/Î²-Catenin Pathway Modulators?â€"A Report from the Renal Tumors Biology-Driven Drug Development Workshop. Molecular Cancer Therapeutics, 2013, 12, 2619-2627. | 4.1 | 28 |
| 44 | Functional characterization of the MTC-associated germline RET-K666E mutation: evidence of oncogenic potential enhanced by the G691S polymorphism. Endocrine-Related Cancer, 2011, 18, 519-527. | 3.1 | 27 |
| 45 | Expression of Iron-Related Proteins Differentiate Non-Cancerous and Cancerous Breast Tumors. International Journal of Molecular Sciences, 2017, 18, 410. | 4.1 | 27 |
| 46 | Ultrastructural cytoskeleton alterations and modification of actin expression in the NIH/3T3 cell line after transformation with Ha-ras-Activated oncogene. Cytoskeleton, 1990, 15, 220-229. | 4.4 | 26 |
| 47 | SH2B1Î² adaptor is a key enhancer of RET tyrosine kinase signaling. Oncogene, 2007, 26, 6546-6559. | 5.9 | 26 |
| 48 | Proteomics study of medullary thyroid carcinomas expressing RET germâ€line mutations: Identification of new signaling elements. Molecular Carcinogenesis, 2009, 48, 220-231. | 2.7 | 26 |
| 49 | Proteomic analysis of cerebrospinal fluid from children with central nervous system tumors identifies candidate proteins relating to tumor metastatic spread. Oncotarget, 2017, 8, 46177-46190. | 1.8 | 24 |
| 50 | Plasma hepcidin in early-stage breast cancer patients: no relationship with interleukin-6, erythropoietin and erythroferrone. Expert Review of Proteomics, 2015, 12, 695-701. | 3.0 | 23 |
| 51 | 4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas. Endocrine-Related Cancer, 2015, 22, 759-775. | 3.1 | 23 |
| 52 | Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. Expert Review of Hematology, 2017, 10, 505-514. | 2.2 | 23 |
| 53 | Proteomic Identification of LASP-1 Down-regulation After RNAi Urokinase Silencing in Human Hepatocellular Carcinoma Cells. Neoplasia, 2009, 11, 207-IN13. | 5.3 | 22 |
| 54 | Elevated levels of the acuteâ€phase serum amyloid are associated with heightened lung cancer risk. Cancer, 2010, 116, 1326-1335. | 4.1 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Activated Leukocyte Cell Adhesion Molecule Expression and Shedding in Thyroid Tumors. PLoS ONE, 2011, 6, e17141. | 2.5 | 21 |
| 56 | Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2015, 16, 19612-19630. | 4.1 | 21 |
| 57 | RET oncoproteins induce tyrosine phosphorylation changes of proteins involved in RNA metabolism. Cellular Signalling, 2006, 18, 2272-2282. | 3.6 | 19 |
| 58 | Proteome profile in Myotonic Dystrophy type 2 myotubes reveals dysfunction in protein processing and mitochondrial pathways. Neurobiology of Disease, 2010, 38, 273-280. | 4.4 | 17 |
| 59 | Lipid accumulation in human breast cancer cells injured by iron depletors. Journal of Experimental and Clinical Cancer Research, 2018, 37, 75. | 8.6 | 17 |
| 60 | Soluble epidermal growth factor receptor isoforms in non-small cell lung cancer tissue and in blood. Lung Cancer, 2012, 76, 332-338. | 2.0 | 16 |
| 61 | A Novel Activating Mutation in the RET Tyrosine Kinase Domain Mediates Neoplastic Transformation. Molecular Endocrinology, 2006, 20, 1633-1643. | 3.7 | 14 |
| 62 | Primary Effusion Lymphoma. American Journal of Pathology, 2014, 184, 618-630. | 3.8 | 14 |
| 63 | Body Mass Index and Serum Proteomic Profile in Breast Cancer and Healthy Women: A Prospective Study. PLoS ONE, 2012, 7, e49631. | 2.5 | 14 |
| 64 | Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells. Biochemical Pharmacology, 2011, 82, 778-788. | 4.4 | 13 |
| 65 | Extracavitary KSHV-positive Solid Lymphoma. American Journal of Surgical Pathology, 2013, 37, 1460-1461. | 3.7 | 13 |
| 66 | Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib. Clinical Biochemistry, 2011, 44, 936-940. | 1.9 | 10 |
| 67 | Applicability of Under Vacuum Fresh Tissue Sealing and Cooling to Omics Analysis of Tumor Tissues. Biopreservation and Biobanking, 2016, 14, 480-490. | 1.0 | 10 |
| 68 | Stratification of clear cell renal cell carcinoma by signaling pathway analysis. Expert Review of Proteomics, 2014, 11, 237-249. | 3.0 | 9 |
| 69 | Cytogenetics and molecular genetics of carcinomas arising from thyroid epithelial follicular cells. Genes Chromosomes and Cancer, 1996, 16, 1-14. | 2.8 | 9 |
| 70 | Proteomic detection of a large amount of SCGFÎ± in the stroma of GISTs after imatinib therapy. Journal of Translational Medicine, 2011, 9, 158. | 4.4 | 8 |
| 71 | Proteomic profile in familial breast cancer patients. Clinical Biochemistry, 2013, 46, 259-265. | 1.9 | 8 |
| 72 | COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. Cancer Letters, 2020, 476, 106-119. | 7.2 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Concurrent pheochromocytoma, paraganglioma, papillary thyroid carcinoma, and desmoid tumor: A case report with analyses at the molecular level. Endocrine Pathology, 1998, 9, 79-90. | 9.0 | 6 |
| 74 | Cell-secreted signals shape lymphoma identity. Seminars in Cancer Biology, 2015, 34, 81-91. | 9.6 | 5 |
| 75 | The molecular basis of thyroid epithelial tumorigenesis. Tumori, 2003, 89, 514-6. | 1.1 | 5 |
| 76 | Chromosome I rearrangements involving the genes TPR and NTRK1 produce structurally different thyroidâ€specific TRK oncogenes. Genes Chromosomes and Cancer, 1997, 19, 112-123. | 2.8 | 1 |
| 77 | Alterations of RNA Metabolism by Proteomic Analysis of Breast Cancer Cells Exposed to Marycin: A New Optically Active Porphyrin. Current Molecular Pharmacology, 2019, 12, 147-159. | 1.5 | 1 |
| 78 | RETMEN2A and RETMEN2B oncoproteins are targets of PP1 inhibitor. Tumori, 2003, 89, 550-2. | 1.1 | 1 |
| 79 | In vitro methylation of the human Ha-ras oncogene (T24) affects its transforming activity on NIH/3T3 cells. Cell Biology International Reports, 1986, 10, 175-175. | 0.6 | 0 |
| 80 | Modulation of the human Ha–1 oncogene expression by DNA methylation. European Journal of Cancer & Clinical Oncology, 1987, 23, 1788-1789. | 0.7 | 0 |
| 81 | Signaling pathway-based stratification of clear cell renal cell carcinoma.. Journal of Clinical Oncology, 2012, 30, 434-434. | 1.6 | 0 |
| 82 | DNA Methylation of the Human Hras1 Gene. , 1989, , 67-73. | | 0 |
| 83 | Abstract 1874: Investigation of the cerebrospinal fluid proteome from central nervous system pediatric tumors using bait loaded hydrogel nanoparticles and mass spectrometry. , 2014, , . | | 0 |
| 84 | Abstract B19: Disruption of energy homeostasis as an approach to block the proliferation of colon carcinomatosis. , 2017, , . | | 0 |
| 85 | Abstract 1908: Search for mediators of the lethal effect of COPZ1 depletion in thyroid tumor cells. , 2018, , . | | 0 |